Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain. 1992

J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
Department of Immunology and Medical Microbiology, TNO Medical Biological Laboratory, Rijswijk, The Netherlands.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D014644 Genetic Variation Genotypic differences observed among individuals in a population. Genetic Diversity,Variation, Genetic,Diversity, Genetic,Diversities, Genetic,Genetic Diversities,Genetic Variations,Variations, Genetic
D015483 HIV Antibodies Antibodies reactive with HIV ANTIGENS. AIDS Antibodies,HIV-Associated Antibodies,HTLV-III Antibodies,HTLV-III-LAV Antibodies,LAV Antibodies,Lymphadenopathy-Associated Antibodies,T-Lymphotropic Virus Type III Antibodies, Human,HIV Associated Antibodies,HTLV III Antibodies,HTLV III LAV Antibodies,Lymphadenopathy Associated Antibodies,T Lymphotropic Virus Type III Antibodies, Human,Antibodies, AIDS,Antibodies, HIV,Antibodies, HIV Associated,Antibodies, HIV-Associated,Antibodies, HTLV III,Antibodies, HTLV-III,Antibodies, HTLV-III-LAV,Antibodies, LAV,Antibodies, Lymphadenopathy Associated,Antibodies, Lymphadenopathy-Associated
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III

Related Publications

J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
June 1995, Journal of virology,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
April 1996, European journal of biochemistry,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
April 1991, Proceedings of the National Academy of Sciences of the United States of America,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
October 1993, Journal of virology,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
December 1988, Journal of virology,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
January 1993, Antisense research and development,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
May 1992, Journal of virology,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
January 1993, Journal of immunology (Baltimore, Md. : 1950),
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
August 1993, Journal of virology,
J D Laman, and M M Schellekens, and Y H Abacioglu, and G K Lewis, and M Tersmette, and R A Fouchier, and J P Langedijk, and E Claasen, and W J Boersma
February 1996, The Journal of experimental medicine,
Copied contents to your clipboard!